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Abstract
Rationale γ-Aminobutyric acid (GABA) is the major inhib-
itory neurotransmitter in the brain and is implicated in the
modulation of central reward processes. Acute or chronic
administration of GABAB receptor agonists or positive
modulators decreased self-administration of various drugs
of abuse. Furthermore, GABAB receptor agonists inhibited
cue-induced reinstatement of nicotine- and cocaine-seeking
behavior. Because of their fewer adverse side effects
compared with GABAB receptor agonists, GABAB receptor
positive modulators are potentially improved therapeutic
compounds for the treatment of drug dependence compared
with agonists.
Objectives and methods We examined whether the acute
effects of the GABAB receptor positive modulator N-
[(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl]-2-methyl-5-[4-
(trifluoromethyl)phenyl]-4-pyrimidinamine (BHF177) on
nicotine self-administration and food-maintained respond-
ing under a fixed-ratio 5 schedule of reinforcement were
maintained after repeated administration. The effects of
acute BHF177 administration on cue-induced nicotine- and
food-seeking behavior, a putative animal model of relapse,
were also examined.
Results Repeated administration of BHF177 for 14 days
decreased nicotine self-administration, with small tolerance
observed during the last 7 days of treatment, whereas
BHF177 minimally affected food-maintained responding.
Acute BHF177 administration dose-dependently blocked
cue-induced reinstatement of nicotine-, but not food-,
seeking behavior after a 10-day extinction period.
Conclusions These results showed that BHF177 selectively
blocked nicotine self-administration and prevented cue-
induced reinstatement of nicotine seeking, with minimal
effects on responding for food and no effect on cue-induced
reinstatement of food seeking. Thus, GABAB receptor
positive modulators could be useful therapeutics for the
treatment of different aspects of nicotine dependence by
facilitating smoking cessation by decreasing nicotine intake
and preventing relapse to smoking in humans.
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Medication
Abbreviations
GABA γ-Aminobutyric acid
Baclofen (R,S)-4-amino-3-(4-chlorophenyl)butanoic
acid
GVG (R,S)-4-aminohex-5-enoic acid
CGP44532 (3-amino-2[S]-hydroxypropyl)-
methylphosphinic acid
CPP Conditioned place preference
CGP7930 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-
propyl)-phenol
GS39783 N,N′-dicyclopentyl-2-methylsulfanyl-5-nitro-
pyrimidine-4,6-diamine
BHF177 N-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl]-2-
methyl-5-[4-(trifluoromethyl)phenyl]-4-
pyrimidinamine
rac-BHFF (R,S)-5,7-di-tert-butyl-3-hydroxy-3-
trifluoromethyl-3H-benzofuran-2-one
FR Fixed ratio
PO Per os
ANOVA Analysis of variance
nAchR Nicotinic acetylcholine receptor
VTA Ventral tegmental area
Introduction
Tobacco addiction, which is partly attributed to the
addictive properties of nicotine (Rose 2007), is among the
most prevalent worldwide health problems (Proctor 2004).
Dependence on tobacco smoking is characterized by
unsuccessful attempts to quit smoking and high rates of
relapse after a period of abstinence (Hughes et al. 2004;
Nides 2008). Currently available smoking cessation thera-
pies include different forms of nicotine replacement
therapy, antidepressants (i.e., bupropion, nortryptiline),
nicotine vaccines, and relatively selective nicotinic α4β2
receptor partial agonists, such as cytisine and the cytisine
derivative varenicline (Zaniewska et al. 2009; Laniado-
Laborin 2010). The abstinence success rates 1 year after
treatment with any of the above therapies is low (Jorenby et
al. 2006; Perkins et al. 2010) and only reaches 24% with
combined pharmacotherapy and behavioral therapy. Novel
targets and mechanisms of action are currently being
investigated to discover new anti-smoking medications,
including compounds that act as positive modulators at γ-
aminobutyric acid B (GABAB) receptors.
Stimulation of GABAB receptors by acute and/or
repeated administration of GABAB receptor agonists
blocked the reinforcing and motivational effects of various
drugs of abuse, such as cocaine, amphetamine, nicotine,
opiates, and ethanol, in rodents (for review, Vlachou and
Markou 2010), as assessed by the self-administration, cue-,
drug-, or stress-induced reinstatement of drug seeking,
intracranial self-stimulation, and conditioned place prefer-
ence procedures. Most relevant to the present studies, acute
and/or repeated administration of GABAB receptor agonists
decreased self-administration of nicotine (Dewey et al.
1999; Corrigall et al. 2000; Fattore et al. 2002; Paterson and
Markou 2002; Paterson et al. 2004, 2005b, 2008). Further-
more, the GABAB receptor agonist (3-amino-2[S]-hydrox-
ypropyl)-methylphosphinic acid (CGP44532) blocked cue-
induced reinstatement of nicotine seeking (Paterson et al.
2005b). Moreover, administration of (R,S)-4-amino-3-(4-
chlorophenyl)butanoic acid (baclofen) or other GABAB
receptor agonists, such as (R,S)-4-aminohex-5-enoic acid
(GVG; inhibits breakdown of GABA) and CGP44532,
blocked the expression and acquisition of drug-induced
conditioned place preference (CPP) when administered either
systemically or directly into different brain regions, such as
the nucleus accumbens and ventral tegmental area (VTA)
(Dewey et al. 1999;L eF o l le ta l .2008; Fattore et al. 2009).
Consistent with the results from animal studies, clinical
evidence showed that baclofen negatively impacted subjec-
tive cigarette pleasure and increased feelings of relaxation,
indicating a possible effect of baclofen on smoking
abstinence and relapse prevention (Cousins et al. 2001).
Most recently, it was shown that baclofen reduced the
number of cigarettes smoked per day and craving, a major
precipitant of relapse (Franklin et al. 2009). Importantly,
baclofen was also more effective than placebo in reducing
cocaine use in cocaine-abstinent humans (Ling et al. 1998;
Shoptaw et al. 2003) and prevented cue-induced craving
and concurrent activation of relevant brain areas, such as
the anterior cingulate and amygdala, in cocaine-abstinent
humans (Brebner et al. 2002). Other preliminary clinical
studies demonstrated that baclofen reduced alcohol con-
sumption and craving, led to abstinence from alcohol
drinking, and treated the alcohol withdrawal syndrome
after either acute or chronic treatment (e.g., Addolorato et
al. 2000, 2002; Flannery et al. 2004; Bucknam 2007;
Leggio et al. 2008). Thus, GABAB receptor agonists appear
to be effective in reversing several drug dependence-related
behaviors.
However, GABAB receptor agonists also have adverse
side effects, such as muscle relaxation, memory impair-
ment, sedation, and tolerance, which restrict their therapeu-
tic potential (Ong and Kerr 2005). On the other hand,
GABAB receptor positive allosteric modulators are devoid
of substantial intrinsic agonistic activity in the absence of
GABA; they do not perturb receptor signaling on their own,
but potentiate the effect of GABA only where and when
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tors (Urwyler et al. 2003). Thus, these compounds have
fewer adverse side effects than GABAB receptor agonists.
Acute administration of a GABAB receptor positive modu-
lator, such as 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-
propyl)-phenol (CGP7930) (Urwyler et al. 2001), N,N'-
dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-
diamine (GS39783) (Urwyler et al. 2003), (R,S)-5,7-di-tert-
butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one
(rac-BHFF) (Malherbe et al. 2008), and N-[(1R,2R,4S)-
bicyclo[2.2.1]hept-2-yl]-2-methyl-5-[4-(trifluoromethyl)
phenyl]-4-pyrimidinamine (BHF177) (Guery et al. 2007),
blocked cocaine, nicotine, and ethanol self-administration
under either fixed- or progressive-ratio schedules of rein-
forcement (Smith et al. 2004; Liang et al. 2006;M a c c i o n ie t
al. 2007, 2008b, 2009; Paterson et al. 2008). BHF177 also
blocked the nicotine-induced enhancement of brain stimula-
tion reward (Paterson et al. 2008).
All of the aforementioned studies evaluated the effects of
the GABAB receptor positive modulators only after acute
administration. However, humans attempting to quit tobac-
co smoking would receive medications daily and for long
periods of time to treat their drug dependence. Thus, the
present study assessed the effects of repeated daily
administration of the GABAB receptor positive modulator
BHF177 on nicotine self-administration in rats.
Furthermore, the effects of acute BHF177 administration
on cue-induced reinstatement of nicotine seeking were
assessed. Cue-induced reinstatement is a widely used
animal procedure for studying the incentive motivational
properties of stimuli previously associated with the primary
rewarding properties of drugs of abuse. This procedure has
been postulated to be relevant to relapse in humans (Epstein
et al. 2006; Kalivas et al. 2006; however see, Katz and
Higgins 2003). Parallel studies on the effects of BHF177
administration on food-maintained responding and cue-
induced reinstatement of food seeking using similar
procedures as those used for the nicotine-motivated
behaviors were also conducted to evaluate the possible
selectivity of the effects of BHF177 on only the rewarding
effects of nicotine and not on the reinforcing effects of a
natural reinforcer such as food.
Methods
Subjects
Male Wistar rats (Charles River, Raleigh, NC, USA),
weighing 250–300 g upon arrival in the laboratory, were
group housed in a temperature- and humidity-controlled
vivarium on a 12 h/12 h reverse light/dark cycle with
unrestricted access to water except during testing. Rats
were food-restricted to 12–20 g/day throughout the experi-
ments (see below), with the exception of the surgical
recovery and initial habituation periods during which rats
had ad libitum access to food and water. Behavioral testing
occurred during the dark phase of the light/dark cycle. All
subjects, animal facilities, and experimental protocols were
in accordance with National Institutes of Health and
Association for the Assessment and Accreditation of
Laboratory Animal Care guidelines and were approved by
the Institutional Animal Care and Use Committee.
Drugs
(−)Nicotine hydrogen tartrate (Sigma, St. Louis, MO, USA)
was dissolved in saline (pH adjusted to 7.0±0.5 with
sodium hydroxide). The solution was then filtered through
a 0.22-μm syringe filter (Fisher Scientific, Pittsburgh, PA,
USA) for sterilization purposes. Nicotine doses are reported
as freebase concentrations, whereas BHF177 doses are
reported as the salt concentration. BHF177 (compound
#27 in Guery et al. 2007) was synthesized and provided by
The Scripps Research Institute (La Jolla, CA, USA;
experiment 1) and Novartis Pharma AG (Basel, Switzerland;
experiment 2). In GTPy
35S assays on CHO-K1 membranes
from GABA-B(1b/2) co-expressing cells, the potency of
BHF177 was 1.7 μM (measured at 1 μM GABA; Guery et
al. 2007), similar to the previously published positive
modulators CGP7930 and GS39783 (Urwyler et al. 2001,
2003), although BHF177 is structurally different than
CGP7930 and GS39783. BHF177 crosses the blood–brain
barrier (Paterson et al. 2008). BHF177 was suspended in
0.5% methylcellulose and administered orally (2 ml/kg, 1 h
pretreatment).
Apparati
Intravenous nicotine self-administration and food-
maintained responding were conducted in 22 Plexiglas
experimental chambers (25×31×24 cm; Med Associates,
St. Albans, VT, USA), each housed in a sound-attenuated
box. One wall of the chamber contained two levers,
measuring ∼3 cm in width and located ∼3 cm above the
metal grid floor of the chamber.
Intravenous catheterization surgery
Rats were anesthetized with an isoflurane/oxygen mixture
(1–1.5% isoflurane) and prepared with a catheter inserted
into the right jugular vein. Catheters were constructed as
previously described (Paterson et al. 2005b, 2008). Animals
were given 7 days to recover from surgery prior to being
trained to lever press for 45-mg food pellets (described
below). All rats were administered 20 mg/day of a drug
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ticarcillin disodium and the β-lactamase inhibitor clavula-
nate potassium (Timentin) for 7 days after surgery.
Additionally, animals received a 0.1-ml infusion of hepa-
rinized saline (33.3 U/ml) before and after each self-
administration session.
Behavioral procedures
Food training and testing The food training and testing
procedures were identical to those previously described
(Liechti et al. 2007; Paterson et al. 2005b, 2008). Rats were
food-restricted (5 g/day) for 48 h prior to starting food
training and received 12 g of rat chow per day, at least 1 h
after the end of the 1 h food training session. Rats were
initially required to press a lever to receive one food pellet
(45 mg Noyes food pellet) on a fixed-ratio 1 timeout 1 s
(FR1 TO 1 s) schedule of reinforcement. Animals pro-
gressed through the sequence FR1 TO 1 s, FR2 TO 10 s,
FR5 TO 20 s only after the successful acquisition of the
previous schedule (>80 pellets/1 h session). After success-
ful acquisition of food-maintained responding, all rats were
maintained on 20 g rat chow per day.
An identical training procedure was implemented for
the subjects used to assess the effects of the test
compounds on food-maintained responding. These rats
were allowed to continue responding for food on an FR5
TO 20 s schedule (1 h sessions/5 days per week). This
testing procedure was identical in all parameters to the
nicotine self-administration procedure (see below). Al-
though levels of responding for nicotine and food self-
administration are quite different, food-maintained respond-
ing is used as a measure of selectivity of a manipulation for
the reinforcing effects of drug and non-drug reinforcers as
well as for assessing potentially non-specific effects of the
drug manipulation on the ability of the animal to perform
the task, such as learning and memory impairments, and
the inability to physically perform the task. Used for these
purposes, food-maintained responding provides highly
valuable information.
Nicotine self-administration under a fixed-ratio schedule of
reinforcement After the successful completion of food
training, rats were allowed to self-administer nicotine
(0.03 mg/kg/infusion; base) by switching the delivery of a
food pellet with the delivery of a nicotine infusion on an
FR5 TO 20 s schedule (1 h sessions/5 days per week). Two
levers were present in the operant testing chamber, only one
of which (the active lever previously paired with food
delivery) was paired with the delivery of a nicotine infusion
(0.1 ml over 1 s; 0.03 mg/kg/inj base; Razel model A
syringe pump, Razel Scientific Instruments, Stamford, CT,
USA). The delivery of an infusion was paired with a cue
light located above the active lever that was lit simulta-
neously with the initiation of the nicotine infusion and
remained illuminated throughout the 20-s timeout period,
during which responding was recorded but not reinforced.
Responses on the inactive lever were recorded but had no
consequences.
Cue-induced reinstatement of nicotine-seeking and food-
maintained responding This procedure is described in
detail in experiment 2 below.
Experimental designs
Experiment 1: effects of repeated administration of
BHF177 on nicotine- and food-maintained responding
under a fixed-ratio schedule of reinforcement After suc-
cessful acquisition of stable nicotine- (n=19) or food- (n=
14) maintained responding, the effects of repeated admin-
istration of BHF177 (0 and 20 mg/kg, PO) were assessed.
BHF177 or its vehicle (0.5% methylcellulose in saline)
were administered orally 1 h before daily test sessions
for 14 consecutive days, after rats exhibited stable
nicotine- or food-maintained responding (<20% variation
in responding for three consecutive days). Nicotine- and
food-responding groups were semi-randomly split into
two groups each (vehicle or 20 mg/kg), so that baseline
responding was equal for the groups (within reinforcer)
assigned to the vehicle or BHF177 treatment conditions.
Previous studies showed that acute administration of 10,
20, and 40 mg/kg BHF177 selectively and dose-
dependently decreased the reinforcing and motivational
properties of nicotine, whereas none of these doses
affected responding for food in a fixed-ratio schedule of
reinforcement, and only the highest dose of BHF177
(40 mg/kg) significantly decreased breakpoints for both
nicotine and food in a progressive-ratio schedule
(Paterson et al. 2008). Thus, we selected the 20 mg/kg
dose, which was devoid of any adverse or nonspecific
effects, for repeated administration in the present study.
Rats were allowed to respond for nicotine or food for
7 days after BHF177/vehicle administration ceased. Body
weights were recorded daily from the beginning of the
repeated BHF177/vehicle administration until the comple-
tion of the experiment.
Experiment2:effectsofacuteBHF177administrationoncue-
induced reinstatement of nicotine-seeking behavior After
successful acquisition of the FR5 TO 20 s schedule (less
than 20% variation in responding during the previous three
baseline sessions), naïve rats were tested under extinction
conditions (withholding of nicotine/food and its associated
cue light) during ten consecutive daily 1-h extinction
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that time, and pumps were not running or making sound.
Responses at both the inactive and active levers were
recorded but had no consequences (i.e., no cue light
illumination, no syringe pump activation, no pump sound,
and no infusion). The reinstatement test phase began 1 day
after the last extinction session. During the reinstatement
test sessions, responses at the active lever resulted in
contingent presentation of the previously nicotine-
associated cue light and the delivery of a saline infusion
instead of nicotine in the nicotine group under an FR5 TO
20 s schedule of reinforcement. Additionally, the cue light
previously associated with nicotine self-administration or
pellet delivery was non-contingently presented for 20 s at
the beginning of the reinstatement session. For the nicotine
group (n=15), the very first reinstatement session was
conducted after vehicle administration (1 h pretreatment,
PO) to ensure that all subjects show reliable reinstatement
after vehicle administration. Then, the effects of BHF177
(0, 2.5, 5, 10, 20, and 40 mg/kg, PO; 1 h pretreatment) were
investigated using a within-subjects Latin square design
that included the assessment of the effects of five doses of
the compound and one vehicle administration. After the
completion of the Latin square design, one final reinstate-
ment session was conducted after vehicle administration
(1 h pretreatment, PO). Thus, there were eight assessments
of cue-induced reinstatement (six reinstatement test ses-
sions as part of the Latin square design and two
reinstatement test sessions after vehicle administration,
one before and one after the Latin square design) that
spanned the entire duration of this experiment and provided
an assessment of the stability of this behavior with repeated
testing and across time. Two of the animals were excluded
from the experiment due to catheter patency issues (i.e., the
number of animals completing the experiment was 13).
Reinstatement sessions were conducted every fourth day
and were separated by three extinction sessions (cue and
nicotine absent) to re-extinguish responding.
For the food group, a between-subjects design was
used because cue-induced food-seeking behavior exhibits
rapid extinction with repeated reinstatement testing,
prohibiting the use of a within-subjects design (Bespalov
et al. 2005; Liechti et al. 2007). Thus, six independent
groups of rats (n=8–9/group) that responded for food
were tested, with each group treated with a different
BHF177 dose (0, 2.5, 5, 10, 20, and 40 mg/kg, PO; 1 h
pretreatment) in a single reinstatement session after the
10-day extinction period. Cue-induced responding includ-
ed the total number of responses emitted on the active
lever, including the responses emitted during the 20-s
timeout period when the cue light was illuminated. The
cue condition used was 20 s illumination of the cue light
located above the active lever.
Statistical analysis
Self-administration data are expressed as the mean number
of infusions/food pellets earned during each daily nicotine
self-administration session throughout the BHF177/vehicle
treatment period. Baseline was defined as the mean number
of rewards earned over the 3 days prior to the initiation of
BHF177/vehicle administration (experiment 1) or the
number of lever presses during the last of the three
extinction sessions preceding each reinstatement session
(experiment 2). Additionally, all data and body weights
obtained from the intravenous self-administration and food-
maintained responding groups were analyzed as the
absolute number of responses and body weights, respec-
tively. Data were analyzed using appropriate two-way
mixed-factor analyses of variance (ANOVAs). In experi-
ment 1, BHF177/Vehicle Treatment was the between-
subjects factor, and Time was the within-subjects factor. In
experiment 2, BHF177 Treatment was the between-subjects
factor, and Session (last day of extinction vs. reinstatement
sessions) was the within-subjects factor. Significant main or
interaction effects were followed by one- or two-way
ANOVAs or the Newman–Keuls post hoc test. The level
of significance was set at 0.05. Statistical analyses were
conducted using Prism v.5.0 (GraphPad, San Diego, CA,
USA) and the Statistical Package for the Social Sciences
v.16.0 (SPSS, Chicago, IL, USA).
Results
Experiment 1: Effects of repeated administration
of BHF177 on nicotine- and food-maintained responding
under a fixed-ratio schedule of reinforcement
For the nicotine group (Fig. 1a), there were significant main
effects of Treatment (F1,255=22.07, p<0.001) and Time
(F15,255=5.903, p<0.0001) and a significant Time×Treat-
ment interaction (F15,255=3.041, p<0.001). Post hoc tests
revealed no difference between the vehicle- and 20 mg/kg
BHF177-treated groups during the baseline days prior to
treatment, whereas a significant BHF177-induced decrease
in nicotine self-administration was found on days 1–7 and
days 9–11 of chronic BHF177 administration compared
with the vehicle-treated group (p<0.05). No differences
were found between groups on the days after the termina-
tion of BHF/vehicle administration. Furthermore, post hoc
tests comparing responding on different days for the BHF177
group indicated a significant decrease in responding on all
days of BHF177 administration compared with the 3-day
baseline before the initiation and after the termination of
treatment(p<0.05).Post hoc tests also indicated a significant
decrease in responding on day 3 of BHF177 administration
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administration compared to days 8–10 and days 12–14 (p<
0.05). Post hoc tests comparing responding on different days
for the vehicle group indicated no statistically significant
effect within the vehicle group across sessions.
Mean (±SEM) body weights during the three baseline
days prior to repeated administration of vehicle/BHF177
were 364.75±8.39 and 374.09±7.21, respectively. Mean
(±SEM) body weights increased to 380.09±7.23 and
383.44±8.22 during the 3 days following vehicle/BHF177
administration, respectively. An ANOVA on body weights
showed no main effect of Treatment, but a main effect of
Time (F15,255=19.59, p<0.0001) and a Time×Treatment
interaction (F15,255=5.404, p<0.0001). However, post hoc
analyses indicated no significant differences in body weights
between the two groups at any time point. These ANOVA
resultsreflectthegradualincreaseinweightovertimeforboth
the BHF177- and vehicle-treated groups and a difference in
the weight increase over time between the two groups.
Responding on the inactive lever was very low. The
number of inactive lever presses (mean±SEM) during the last
three nicotine self-administration sessions prior to initiating
repeatedBHF177 orvehicle administrationwas 1.08±0.5 and
1.75±1.19 for the two groups, respectively. Analysis of
inactive lever responses showed no statistically significant
effects on inactive lever responses (data not shown).
For the food-responding groups (Fig. 1b), there were
significant main effects of Treatment (F15,180=4.987, p<
0.05) and Time (F15,180=2.271, p<0.01) and a significant
Time×Treatment interaction (F15,180=2.345, p<0.01). Post
hoc tests revealed no difference between the vehicle- and
20 mg/kg BHF177-treated groups during the baseline days
prior to treatment, whereas a significant BHF177-induced
decrease in food-maintained responding was found on
day 2 and days 5–6 of chronic BHF177 administration
compared with the vehicle-treated group (p<0.05). Further-
more, post hoc tests comparing responding on different
days for the BHF177 group indicated a significant decrease
in responding on day 2 of BHF177 administration
compared with days 9 and 13 (p<0.05). There were no
statistically significant differences among days for the
BHF177 group, compared with the pretreatment baseline.
Post hoc tests comparing responding across days for the
vehicle group indicated significantly increased responding
on all days of vehicle treatment and during the baseline
after the termination of treatment compared with baseline
responding before the initiation of treatment (p<0.05).
Mean (±SEM) body weights during the baseline days
prior to repeated administration of BHF177/vehicle were
386.57±9.42 and 389.056±6.82, respectively. Mean
(±SEM) body weights increased to 428.35±11.21 and
449.21±12.07 during the 3 days after vehicle/BHF177
administration, respectively. An ANOVA on body weights
showed a significant main effect of Time (F15,180=139.70,
p<0.0001), but no effect of Treatment and no Time×
Treatment interaction.
Responding on the inactive lever was very low. The
number of inactive lever presses (mean±SEM) during the
baseline period prior to initiating repeated BHF177 or vehicle
administration was 0.76±0.3 and 0.57±0.37 for the two
groups, respectively. Analysis of the inactive lever responses
showed no statistically significant effects (data not shown).
Experiment 2: Effects of acute BHF177 administration
on cue-induced reinstatement of nicotine-seeking behavior
For the nicotine group (Fig. 2a), BHF177 blocked cue-
induced reinstatement of nicotine seeking, reflected in a
Fig. 1 Effects of repeated BHF177/vehicle treatment for 14 days on a
nicotine self-administration and b food-maintained responding. Data
are expressed as nicotine infusions or food pellets earned under a
fixed-ratio 5 schedule of reinforcement during 1-h test sessions. The
abscissa shows the pre-treatment baseline (B), the 14 days of BHF177/
vehicle treatment, and the post-treatment baseline after discontinuing
BHF177/vehicle treatment (B; the two time-points overlap on the
graph for the nicotine group). Closed squares (black) represent the
groups receiving vehicle. Open squares (white) represent the groups
receiving 20 mg/kg BHF177. *p<0.05, significant differences
between the vehicle and 20 mg/kg of BHF177 treatment groups on
the same days of testing;
+p<0.05, significant differences between
reinforcers earned on the various days of BHF177/vehicle treatment
compared with the pretreatment baseline within each group;
#p<0.05,
significant differences between reinforcers earned on day 3 compared
with days 8 and 10 and day 4 compared with days 8–10 and days 12–
14 (a), and significant differences between reinforcers earned on day 2
compared with days 9 and 13 (b)
122 Psychopharmacology (2011) 215:117–128main effect of Treatment (F5,144=6.471, p<0.0001), a main
effect of Session (extinction session preceding the rein-
statement session vs. the reinstatement session—F1,144=
6.519, p<0.05), and a statistically significant Treatment×
Session interaction (F5,144=2.926, p<0.05). Post hoc
comparisons indicated that the reinstatement sessions
preceded by administration of vehicle or any of the three
lower BHF177 doses were characterized by a significantly
increased number of responses compared with the extinc-
tion sessions preceding these reinstatement sessions
(vehicle, p<0.01; 2.5 and 5 mg/kg, p<0.05), but not when
the highest doses of BHF177 (10, 20, and 40 mg/kg) were
administered. Confirming the above results, a follow-up
one-way ANOVA on only the cue-induced reinstatement
sessions, with Treatment as the one within-subject factor,
showed a significant effect of BHF177 administration on
cue-induced reinstatement of nicotine seeking (F5,72=
5.368, p<0.0001). A follow-up one-way ANOVA on the
extinction sessions, with Treatment as the one within-
subject factor, showed no difference between the different
extinction sessions preceding the reinstatement sessions,
demonstrating the stability of responding during the
extinction periods.
Additionally, an ANOVA on the three different vehicle
reinstatement sessions (i.e., one immediately after the 10-
day extinction phase, one as part of the Latin square design,
and one after the completion of the Latin square design)
revealed a main effect of Treatment (F2,72=9.86, p<0.001),
a main effect of Session (F1,72=24.86, p<0.001), and a
Treatment×Session interaction (F2,72=3.279, p<0.05). Post
hoc tests indicated that reinstatement session 1 (p<0.001),
reinstatement session 2 (p<0.01), and reinstatement session
3( p<0.05) were characterized by higher response rates than
the extinction sessions that preceded each reinstatement
session. Furthermore, post hoc tests indicated a significant
difference between reinstatement session 1 and reinstate-
ment sessions 2 and 3 (p<0.05), whereas there was no
statistically significant difference between extinction
sessions (Fig. 3).
An ANOVA on the number of inactive lever presses
during the extinction and reinstatement sessions showed no
effect of Treatment or Session and no Treatment×Session
interaction (Table 1). Mean (±SEM) body weights at the
time of the first reinstatement of nicotine seeking were
434.62±7.40 g.
For the food group (Fig. 2b), there was a statistically
significant increase in responding during the reinstatement
sessions (main effect of Session—F1,88=56.54, p<0.0001),
but BHF177 did not block cue-induced reinstatement of
food-seeking behavior (no main effect of Treatment and no
significant Treatment×Session interaction).
An ANOVA on the inactive lever presses during the
extinction and reinstatement sessions showed a small effect
of Session (F1,88=4.360, p<0.05), but no effect of
Treatment and no Treatment×Session interaction (Table 1).
Mean (±SEM) body weights at the time of the first
reinstatement of food seeking were 374.33±5.67 g.
Discussion
The results indicate that repeated administration of 20 mg/kg
ofthenewlysynthesizedGABAB receptor positive modulator
BHF177 significantly decreased nicotine self-administration,
with small tolerance development on day 8 and during the
last 3 days of chronic treatment. After termination of
repeated BHF177 treatment, nicotine self-administration
returned to the same levels of responding as before
BHF177 treatment. Repeated administration of 20 mg/kg
BHF177 only minimally decreased food-maintained
Fig. 2 Effects of the GABAB receptor positive modulator BHF177 on
cue-induced reinstatement of a nicotine-seeking and b food-seeking
behavior. Data are expressed as the number of active lever presses
during the extinction session (last extinction session out of the three
conducted between reinstatement sessions) preceding each reinstate-
ment session (light gray bars) and the reinstatement session (dark
gray bars). The abscissa shows BHF177 doses (0, 2.5, 5, 10, 20, and
40 mg/kg, PO) administered before the reinstatement session. *p<
0.05, **p<0.01, significant differences in responding between the
reinstatement day and the preceding extinction day.
###p<0.001,
significant differences in responding between the 10, 20, and 40 mg/kg
doses compared with vehicle and the 2.5 and 5 mg/kg doses.
++p<0.01,
significant difference between the 5 and 20 mg/kg doses
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days 5–6). Furthermore, the results showed that cue-induced
reinstatement of nicotine seeking dose-dependently de-
creased after acute administration of BHF177 at the three
highest doses tested (10, 20, and 40 mg/kg), whereas the two
lowest doses (2.5 and 5 mg/kg) were ineffective. Cue-
induced reinstatement of food-maintained responding was
not affected by BHF177 administration at any of the doses
tested. Additionally, BHF177 only decreased responding on
the active lever and not on the inactive lever. Altogether, the
latter two findings indicate that the effects of BHF177 are
likely attributable to a selective effect on the motivational
properties of stimuli predictive of nicotine availability and
not on the motivational properties of stimuli associated with
natural reinforcers, such as food.
Tolerance development to the effects of BHF177 was
seen at the same time point (day 8) as after administration
of the GABAB receptor agonist CGP44532 (Paterson et al.
2005b). However, there was still a strong effect of BHF177
on nicotine self-administration on days 9–11 when there
appeared to be small tolerance to the effects of the GABAB
receptor agonist. Importantly, the magnitude of effect of
repeated BHF177 treatment was larger (∼50–90%) than the
effect observed with CGP44532 (∼40%) at doses at which
both compounds did not affect responding for food.
Overall, the results show an improved pharmacological
profile of GABAB receptor positive modulators in terms of
less tolerance development and a greater magnitude of
effect on nicotine self-administration compared with a
GABAB receptor agonist.
The effects of repeated BHF177 administration on
nicotine self-administration are consistent with the dose-
dependent decrease in acquisition of ethanol intake in
Sardinian alcohol-preferring rats after 5 days of adminis-
tration of either of two GABAB receptor positive modu-
lators, CGP7930 or GS39783 (Orru et al. 2005). Similar
effects were observed after acute administration of the
GABAB receptor positive modulators CGP7930, GS39783,
BHF177, and rac-BHFF on alcohol self-administration
under fixed- (Liang et al. 2006; Maccioni et al. 2007,
2009, 2010) or progressive-ratio schedules of reinforcement
(Maccioni et al. 2008b), whereas none of these compounds
affected responding for natural reinforcers, such as water or
sucrose (Liang et al. 2006;M a c c i o n ie ta l .2007).
The effects of BHF177 on cue-induced reinstatement of
nicotine seeking are consistent with the effects of GABAB
receptor agonists on cue-induced reinstatement of seeking
for other drugs of abuse. The GABAB receptor agonists
baclofen, CGP44532, and SKF97541 blocked reinstatement
of nicotine, cocaine, heroin, and alcohol seeking induced
eitherbyapriminginjectionofthedrugorbypresentationofa
cue previously associated with drug delivery (Campbell et al.
1999; Paterson et al. 2005b; Filip and Frankowska 2007;
Spano et al. 2007; Weerts et al. 2007; Maccioni et al. 2008a);
in some of these studies, the compounds also affected cue-
induced reinstatement of food- and sucrose-seeking behavior
(Paterson et al. 2005b; Filip and Frankowska 2007),
However, consistent with our results, the GABAB receptor
positive modulator CGP7930 did not affect reinstatement of
food seeking (Filip and Frankowska 2007).
To assess the stability of cue-induced reinstatement of
nicotine-seeking behavior, three different reinstatement
sessions after vehicle administration were conducted during
the cue-induced reinstatement experiment. Responses dur-
ing the first vehicle reinstatement session, which was
conducted immediately after the 10-day extinction phase,
were higher than responses during the two subsequent
reinstatement sessions, which were conducted as part of the
within-subjects Latin square design or after the completion
of the Latin square design. Notably, the two subsequent
reinstatement sessions were characterized by a similar
Fig. 3 Effect of vehicle administration on cue-induced reinstatement
of nicotine over time and with repeated cue-induced reinstatement
testing. Three cue-induced reinstatement sessions (R1, R2, R3) were
conducted as part of the cue-induced reinstatement experiment.
Extinction sessions (light gray bars) are the last extinction sessions
(out of three sessions conducted in-between reinstatement sessions)
preceding the reinstatement sessions (dark gray bars). The abscissa
shows the extinction and reinstatement sessions. The ordinate shows
the number of active lever presses per session. Avehicle injection was
administered before each of these reinstatement sessions. The first
reinstatement session was conducted immediately after the 10-day
extinction phase (R1), before the initiation of the within-subjects Latin
square design of experiment 2. The second reinstatement session was
conducted as part of the within-subjects Latin square design of
experiment 2 and corresponds to the vehicle condition presented in
Fig. 2a (R2). The third reinstatement session was conducted after
completing the Latin square design of experiment 2 (R3). Responses
during the first vehicle reinstatement session are higher than responses
during the two subsequent reinstatement sessions. The subsequent two
reinstatement sessions were characterized by similar numbers of
responses. *p<0.05, **p<0.01, ***p<0.001, significant differences
between responding during the reinstatement sessions and responding
on the preceding extinction session.
#p<0.05,
##p<0.01, significant
differences in responding between R1 and R3 or between R1 and R2
124 Psychopharmacology (2011) 215:117–128number of responses. Thus, cue-induced reinstatement of
nicotine-seeking behavior is not rapidly extinguished, and a
within-subjects design for assessing the effects of various
doses of a test compound is suitable for these studies after
an initial reinstatement session is conducted under vehicle
conditions.
GABAB receptors are widely distributed in several areas
of the brain reward circuitry where they negatively
modulate reward, reinforcement, and reinstatement of drug
seeking (Laviolette and van der Kooy 2003; Sagara et al.
2008;X ie ta l .2009; Yang et al. 2009). VTA dopaminergic
neurons receive descending GABAergic inputs from the
ventral pallidum and nucleus accumbens (Walaas and
Fonnum 1979, 1980; Sugita et al. 1992) that inhibit
dopaminergic tone (Klitenick et al. 1992; Engberg et al.
1993). GABAB receptors are co-localized with nicotinic
acetylcholine receptors (nAchR), mainly α4β2 and α7
nAchR subtypes, on inhibitory GABAergic neurons and
interneurons in the VTA (Mansvelder and McGehee 2002).
Nicotine exerts its effects on GABAergic neurotransmission
through nicotinic receptors located on these neurons.
BHF177 administration likely induced its behavioral effects
on nicotine self-administration by augmenting the effects of
endogenously released GABA on GABAB receptor-
mediated inhibition of dopaminergic and glutamatergic
neuronal activity in areas enriched with GABAB receptors,
such as the VTA, nucleus accumbens, ventral pallidum,
hippocampus, and extended amygdala. These brain sites
have been implicated in the effects of GABAB receptor
agonists on the rewarding effects of drugs of abuse (Panagis
and Kastellakis 2002; Fadda et al. 2003; Zarrindast et al.
2006; Rogers and See 2007).
Interestingly, decreased GABAB1 and/or GABAB2
mRNA receptor expression was found in the rat hippocam-
pus and/or areas of the prefrontal cortex immediately after
discontinuation of chronic nicotine administration or pas-
sive cigarette smoke inhalation (Li et al. 2002, 2004).
However, Paterson and colleagues (2005a) showed that
chronic subcutaneous nicotine infusion for 7–24 days did
not induce significant changes in GABAB receptor-
mediated regulation of brain reward function. In the
Paterson study, systemic administration of either the
GABAB receptor agonist GVG or CGP44532, and intra-
VTA administration of CGP44532 did not produce differ-
ential effects on brain reward function, assessed by
intracranial self-stimulation, between saline- and nicotine-
treated rats, with nicotine/saline onboard at the time of
testing. The present studies were also conducted while
subjects were exposed to nicotine. Although the Li and
colleagues findings suggest decreased GABAB receptor
expression after chronic nicotine exposure and withdrawal
from nicotine, the findings by Paterson and colleagues
indicate a lack of functional adaptation of GABAB
receptors with nicotine on board. Thus, chronic exposure
to nicotine during the 6 weeks of self-administration
(4 weeks before the initiation of BHF177 treatment and
2 weeks during BHF177 treatment) may have altered
GABAB receptor expression (consistent with the Li find-
ings), but the net function of GABAB receptors may not
have been altered (consistent with the Paterson findings).
Importantly, less tolerance developed during the last
7 days of the repeated BHF177 treatment than the tolerance
seen after repeated administration of the GABAB receptor
agonist CGP44532 (Paterson et al. 2005b). Accordingly,
repeated administration of the GABAB receptor agonist
baclofen reduced electrophysiological and pharmacological
responsiveness to baclofen on both pre- and postsynaptic
GABAB receptors in the prefrontal cortex, spinal cord, and
Table 1 Mean (±SEM) responses on the inactive lever (including timeout responses) during the third extinction session (out of the three
extinction sessions that took place in-between reinstatement sessions) prior to each reinstatement day, and during the reinstatement sessions
Experimental group Group size Reinforcer Responding on the inactive
lever during extinction
Responding on the inactive
lever during reinstatement
Vehicle n=13 Nicotine 3.15±0.99 4.77±1.04
2.5 mg/kg BHF177 n=13 Nicotine 4.51±1.29 3.67±0.90
5 mg/kg BHF177 n=13 Nicotine 4.45±2.31 5.11±2.57
10 mg/kg BHF177 n=13 Nicotine 4.15±1.77 2.93±1.21
20 mg/kg BHF177 n=13 Nicotine 2.84±0.67 1.85±0.76
40 mg/kg BHF177 n=13 Nicotine 2.38±0.73 2.46±1.44
Vehicle n=9 Food 3.55±1.01 1.67±0.40
2.5 mg/kg BHF177 n=9 Food 3.00±0.76 1.44±0.50
5 mg/kg BHF177 n=8 Food 2.13±0.58 0.88±0.22
10 mg/kg BHF177 n=8 Food 3.25±1.32 3.12±1.76
20 mg/kg BHF177 n=8 Food 7.00±2.35 3.63±0.91
40 mg/kg BHF177 n=8 Food 3.75±2.22 5.50±2.85
Psychopharmacology (2011) 215:117–128 125hippocampus in rats (Malcangio et al. 1995; Wetherington
and Lambert 2002). Thus, the tolerance seen with GABAB
receptor agonists is likely attributable to the repeated
agonist action on the receptor, whereas the less tolerance
development with the positive modulator is likely attribut-
able to the fact that such compounds only enhance the
activity of endogenous GABA on the receptor.
In summary, the present studies showed that repeated
administration of the GABAB receptor positive modulator
BHF177 decreased the reinforcing effects of nicotine with
small tolerance development during the last 7 days of the
chronic treatment compared with previously observed
tolerance during chronic treatment with the GABAB
receptor agonist CGP44532 (Paterson et al. 2005b).
Repeated BHF177 administration minimally decreased
food-maintained responding. Moreover, acute administra-
tion of BHF177 selectively and dose-dependently blocked
cue-induced reinstatement of nicotine-, but not food-,
seeking behavior. These findings provide clear evidence
that GABAB receptors play a significant role in the
regulation of reinstatement processes and that activation
of these receptors blocks the motivational effects of stimuli
associated with nicotine that lead to reinstatement. Thus,
GABAB receptor positive modulators may be used thera-
peutically for the treatment of different aspects of nicotine
dependence by reducing nicotine intake and preventing
relapse in humans.
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